HF 10

Drug Profile

HF 10

Alternative Names: HF10; Msc 2; TBI-1401

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ms Science; Nagoya University
  • Developer Takara Bio
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Head and neck cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 23 Aug 2017 Takara Bio plans a phase I trial for Pancreatic cancer (Late-stage disease, Inoperable/unresectable, Adjunctive therapy) in Japan (NCT03252808)
  • 18 Aug 2017 Bristol-Myers Squibb, Takara Bio and University of Utah plan the phase II Neo-NivoHF10 trial for Melanoma (Late-stage disease, Neoadjuvant therapy, Metastatic disease, Combination therapy, Second-line therapy or greater, In adults, In the elderly) in USA (IV) (NCT03259425)
  • 02 Jun 2017 Final adverse events and efficacy data from a phase II trial in Melanoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top